Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Diluted EPS of $12.85 per share (loss) for fiscal year 2025.
MADRIGAL PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$12.85 | +41.3% |
| 2024 | -$21.90 | -9.6% |
| 2023 | -$19.99 | -16.0% |
| 2022 | -$17.23 | -17.8% |
| 2021 | -$14.63 | -11.8% |
| 2020 | -$13.09 | -1209.0% |
| 2011 | -$1.00 | -7.5% |
| 2010 | -$0.93 | -140.1% |
| 2009 | $2.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.08 | -3.3% | -167.4% |
| June 30, 2025 | -$1.90 | +73.2% | +42.8% |
| March 31, 2025 | -$3.32 | +55.0% | +32.5% |
| September 30, 2024 | -$4.92 | +7.9% | +30.7% |
| June 30, 2024 | -$7.10 | -51.4% | +3.8% |
| March 31, 2024 | -$7.38 | -74.5% | -38.2% |
| September 30, 2023 | -$5.34 | -12.4% | -13.9% |
| June 30, 2023 | -$4.69 | -13.3% | -10.9% |
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +41.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, MADRIGAL PHARMACEUTICALS, INC.’s diluted eps has declined by 653.9% (from $2.32 per share to $12.85 per share (loss)).
- The most recent figure is from MADRIGAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: